2invest AG
SYGNIS signs non-exclusive distribution agreement with SOPACHEM for TruePrime(TM) product family in Belgium
SYGNIS AG / Key word(s): Agreement
Press Release SYGNIS signs non-exclusive distribution agreement with SOPACHEM for TruePrime(TM) product family in Belgium – SOPACHEM is a specialized distributor with focus on life sciences, diagnostics, biobanking and analytical applications – Recently launched TruePrime(TM) products in stock for immediate distribution – TruePrime(TM) is a powerful amplification tool addressing key challenges in next generation sequencing (NGS) Madrid, Spain and Heidelberg, Germany, March 18th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced a distribution agreement with SOPACHEM for the commercialization of the TruePrime(TM) product family developed by SYGNIS and designed for whole genome amplification (WGA) in Belgium. Under the terms of the agreement, SOPACHEM will promote, market, sell and support TruePrime(TM) products for primer-free WGA in Belgium. TruePrime(TM) is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics. SOPACHEM is a specialized distributor with a strong focus on life sciences, diagnostics, biobanking and analytical applications with a broad portfolio of innovative products and technologies for NGS, polymerase chain reaction (PCR) analysis, DNA extraction and purification, transfection, bio-imaging and instrumentation. Besides its headquarters in Belgium, SOPACHEM runs additional offices in the Netherlands and in Luxembourg. TruePrime(TM) WGA products are available in two formats, containing 25 or 100 reactions. Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product is made available and can also be directly ordered through SYGNIS’ own TruePrime(TM) online shop under www.sygnis.com/shop. About TruePrime(TM) TruePrime(TM) is the brand name of a revolutionary novel multiple displacement amplification (MDA) technology and one of the key products in SYGNIS’ portfolio. TruePrime(TM) is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand-displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers. The resulting benefits of this innovative approach are enormous and include the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime(TM) shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent. For further information please contact:
About SYGNIS AG: www.sygnis.com ### Disclaimer 2015-03-18 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | SYGNIS AG | |
Im Neuenheimer Feld 515 | ||
69120 Heidelberg | ||
Germany | ||
Phone: | 06221 454-6 | |
Fax: | 06221 454-700 | |
E-mail: | contact@sygnis.de | |
Internet: | www.sygnis.de | |
ISIN: | DE000A1RFM03 | |
WKN: | A1RFM0 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
334343 2015-03-18 |